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418Objective: Recombinant factor VIIa can decrease postoperative bleeding after cardiac surgery. However, the
potential for recombinant factor VIIa to cause early vascular graft occlusion at the site of new vascular anasto-
moses has not been fully explored.We hypothesized that recombinant factor VIIa would cause a dose-dependent
reduction in vascular graft patency in rabbits.
Methods: Reversed end-to-end interpositional vein grafts were sutured into the carotid artery of heparinized
rabbits, and then recombinant factor VIIa (300 mg/kg, 90 mg/kg, or 20 mg/kg intravenously) or placebo was
administered (n¼ 16/group). Graft patency was assessed at 24 hours using a vascular ultrasound probe. Factor
VII activity levels were measured using a prothrombin time-based assay. In different rabbits, the patency of
venous end-to-side anastomoses and simple carotid arterial repairs was assessed (recombinant factor VIIa,
300 mg/kg vs placebo, n ¼ 8/group). Data were analyzed using Fisher’s exact test, t tests, or analysis of
variance.
Results: Physiologic variables (activated clotting time, hemoglobin, pH, Pao2) and vessel diameter were not
different between groups. Vein graft patency was reduced (93.8%, 81.2%, 13.8%, and 6.3%) as factor VII
activity levels increased (1.8  0.4, 4.4 2.1, 11.8 4.7, and 23.6  16.9 U/mL, respectively) with increasing
doses of recombinant factor VIIa administered (0, 20, 90, and 300 mg/kg, respectively, P<.05). Patency in the
arterial repairs and end-to-side venous grafts was also reduced in recombinant factor VIIa-treated rabbits
(P<.05 for both).
Conclusions: This study suggests that recombinant factor VIIa is associated with a dose-dependent increase in
fresh vascular graft occlusion. Higher doses of recombinant factor VIIa may be associated with increased
thrombotic outcomes. (J Thorac Cardiovasc Surg 2011;142:418-23)Coronary artery bypass graft surgery is commonly performed
to provide myocardial revascularization through arterial and
venous bypass grafts. Postoperative hemorrhage occurs in
up to 20% of these patients and has been associated with
increased morbidity and mortality. Clinical management of
postoperative bleeding includes multimodal therapeutic
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The Journal of Thoracic and Cardiovascular Surgof allogeneic red blood cells, platelets, and coagulation
factors. However, each of these therapies has been associated
with significant risks and complications.A treatment that pro-
motes hemostasis without compromising patency would be
a valuable addition to current clinical practice. Recombinant
factor VIIa (rFVIIa) is an approved therapy for treatment for
bleeding episodes in patients with hemophilia, which
has recently been used off-label to treat refractory bleeding
in patients undergoing cardiac surgery.1-5 The profound
hemostatic effect of rFVIIa is thought to be a function of
site-specific thrombin generation by tissue factor-mediated
activation of coagulation or by tissue factor-independent
thrombin generation on activated platelets at sites of vascular
injury.6 Although an increasing number of reports have
described the successful use of rFVIIa to treat bleeding after
cardiac surgery, the safety and efficacy of this treatment have
not been well studied. This is of particular importance in
patients with cardiovascular diseasewith fresh vascular anas-
tomoses. The potential hemostatic benefits of rFVIIa could be
negated if tissue factor expression and thrombin generation at
the site of new anastomoses resulted in graft narrowing orery c August 2011
Abbreviations and Acronyms
ACT ¼ activated clotting time
rFVIIa ¼ recombinant factor VIIa
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with aprotinin and erythropoietin emphasize the importance
of properly evaluating hemostatic drugs before widespread
clinical use.7-9 This study was designed to test the
hypothesis that the administration of rFVIIa reduces graft
patency at the site of new vascular anastomoses in a dose-
dependent fashion, using a rabbit model.
MATERIALS AND METHODS
Animal Model and Surgical Preparation
All animal protocolswere approved by theAnimalCare andUseCommit-
tee at StMichael’s Hospital in accordancewith the requirements of Canadian
AnimalCareCommittee.NewZealandWhite rabbits (3–4kg)were premedi-
cated with ketamine (10 mg/kg) and xylazine (2 mg/kg), and anesthetized
with1% to 3% isoflurane inoxygendeliveredvia facemask and spontaneous
ventilation. Body temperature was maintained using radiant warming
lamps. The ear artery was cannulated with a 25 G catheter for direct blood
pressure measurement and blood sampling for blood gas analysis and
measurement of hemoglobin concentration using co-oximetry (Radiometer
ALB 500 and OSM 3, London Scientific, London, Canada). An ear vein
was cannulated with a 22-g catheter for administration of study drug or
saline vehicle. Intravenous isotonic saline was administered continuously at
approximately 2 mL/kg/h throughout surgery to replace insensible fluid
losses.
Through a midline neck incision, the right carotid artery was isolated
and dissected free. A 2- to 3-cm portion of the ipsilateral jugular vein
was then isolated, excised, and flushed with heparinized saline. The ani-
mals were then systemically anticoagulated with heparin (250–300 IU/kg
intravenously) to achieve and maintain a target activated clotting time
(ACT) of greater than 250 seconds during carotid occlusion and graft sutur-
ing. One of 2 experimental protocols was then performed, as outlined
below. All anastomoses were performed with interrupted 9-0 Prolene
sutures (AROSurgical, Newport Beach, Calif). Surgical hemostasis and
graft patency were always ensured by inspection before wound closure.
The isoflurane was then discontinued, and the animals were allowed to
recover.
Experimental Protocol 1: Recombinant Factor VIIa
Dose Response
In protocol 1, an interpositional graft of reversed jugular vein was fash-
ioned in the carotid artery using 2 artery-to-vein anastomoses. The animals
then received rFVIIa (Niastase; NovoNordisk, Mississauga, Canada) or
placebo (n ¼ 16 per group) in a blinded fashion, so that neither the person
performing the anastomoses nor the person assessing the primary outcome
was aware of treatment assignment. The study drug was prepared in
accordance with the manufacturer’s recommendations immediately before
administration and injected intravenously via the ear vein. Three dosing
regimens of rFVIIa were studied: 300, 90, and 20 mg/kg. These regimens
were chosen because they span the range of doses given to humans. The
currently approved dose for hemophiliac patients is 90 mg/kg. Before and
approximately 20 minutes after drug (or placebo) administration, blood
was drawn and centrifuged (3400 rpm 3 12 minutes), and citrated plasma
was frozen at80 degrees for subsequentmeasurement of factor VII activity
levels (see below).The Journal of Thoracic and CaExperimental Protocol 2: Effect of High-Dose
Recombinant Factor VIIa onArterial and End-to-Side
Venous Anastomoses
In protocol 2, 2 different anastomotic techniques were evaluated in the
same animal. The right carotid artery was ligated at its midpoint, and the
vein segment was used as a bypass graft rather than an interposition graft
by creating 2 end-to-side anastomoses. In addition, the contralateral carotid
artery was transected and then repaired with a single end-to-end arterial
repair. The end-to-side vein graft anastomoses were performed to model
a saphenous vein to coronary artery graft. The simple arterial repair was
performed to model vascular grafts using arterial conduits. In this protocol,
the highest dose of rFVIIa was used (300 mg/kg) to maximize the ability
to detect potential differences in graft occlusion with different graft
techniques.
Outcomes/Measurements
Primary outcome. The primary outcome of this study was graft
occlusion at 1 day as assessed by ultrasound or direct visual inspection
in rabbits anesthetized as described. The investigators performing the anas-
tomoses or assessing the primary outcomewere blinded to study treatment.
An HDI 5000cv ultrasound system (Philips Ultrasound, Mississauga,
Canada), equipped with a high-frequency (15 MHz) linear array vascular
probe (CL15-7), was used to visualize the body of the graft, including all
anastomotic sites, using standard B-mode ultrasound in longitudinal and
transverse axes. The grafts were defined as patent if therewas demonstrable
flow through them or there was no evidence of occlusion at autopsy. Filling
defects representing intraluminal thrombi within the graft were identified,
and the dimensions were measured in 2 orthogonal planes. Blood flow
through patent grafts was assessed using standard color and spectral
Doppler techniques. Quantitative blood flow measurements were per-
formed in the proximal and distal carotid arteries using standard quantita-
tive volume flow techniques (HDI5000cv). This technique uses mean
velocities and vessel diameters to calculate volumetric flow through vessels
and has been validated.10
Factor VII activity levels in the citrated plasma samples were measured
in the dose-response experiments using standard 1-stage coagulation end-
point techniques, with rabbit brain thromboplastin (IL Test PT-Fibrinogen
HS; Instrumentation Laboratory, Bedford, Mass) and immunoadsorbed
factor VII deficient plasma (Hemoliance Deficient Plasma; Beckman-
Coulter Canada, Mississauga, Ontario, Canada). The calibration curve
used reference plasma calibrated against the World Health Organization
standard.
Statistical Analyses
Statistical analyses were performed using the SAS System forWindows,
version 8.02 (SAS Institute Inc, Cary, NC). The sample size was estimated
assuming a 95% patency rate in the placebo group based on previous
studies, a 40% reduction with rFVIIa, an alpha error of 0.05, and a beta
of 0.20 (power 0.80).The primary outcome was assessed using Fisher’s
exact test. Other data were analyzed with t tests or 2-way analysis of vari-
ance for continuous variables as appropriate. When a significant F-ratio
was present, multiple comparisons were made using Dunnett’s and Tukey’s
tests. All data are reported as mean  standard deviation or frequency 
95% confidence intervals.RESULTS
Fifteen of 95 rabbits entered into the protocol were
excluded (surgical difficulties with anastomoses [n ¼ 10],
perioperative death [n ¼ 2], problems with anticoagulation
[n¼ 2], and problems with data acquisition [n¼ 1]), leaving
a total of 80 animals. Sixty-four rabbits were used in therdiovascular Surgery c Volume 142, Number 2 419
TABLE 1. Physiologic variables
Variable Protocol group rFVIIa dose Baseline Postheparin
ACT Protocol 1 0 m/kg (placebo) 71  3 282  90*
20 m/kg 73  7 318  66*
90 m/kg 76  9 268  91*
300 m/kg 81  15 329  93*
Protocol 2 0 96  20 389  93*
300 96  23 379  51*
Hb Protocol 1 0 m/kg (placebo) 122  7 115  12
20 m/kg 119  8 113  9
90 m/kg 118  8 117  8
300 m/kg 125  10 121  8
Protocol 2 0 108  9 106  8
300 113  10 110  12
MAP Protocol 1 0 m/kg (placebo) 70  7 64  8
20 m/kg 71  4 62  9
90 m/kg 63  7y 56  11y
300 m/kg 70  4 63  4
Protocol 2 0 67  7 65  13
300 64  12 66  17
pH Protocol 1 0 m/kg (placebo) 7.38  0.04 7.35  0.08
20 m/kg 7.34  0.04 7.31  0.07
90 m/kg 7.36  0.06 7.36  0.09
300 m/kg 7.35  0.04 7.36  0.09
Protocol 2 0 7.30  0.10 7.28  0.13
300 7.33  0.09 7.26  0.14
Pao2 Protocol 1 0 m/kg (placebo) 433  45 404  41
20 m/kg 429  55 397  60
90 m/kg 401  79 382  59
300 m/kg 452  34 446  64
Protocol 2 0 354  76 359  85
300 379  68 339  77
rFVIIa, Recombinant factor VIIa; ACT, activated clotting time; Hb, hemoglobin;
MAP, mean arterial pressure. *P<.05 compared with baseline value. yP<.05 com-
pared with other groups at that time point.
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were used in experimental protocol 2 (n ¼ 8 per group).
The average weight of the rabbits was not different between
groups (3.8 0.5 kg).
Protocol 1: Dose Response Protocol
Physiologic variables. There were no significant differ-
ences in baseline physiologic variables between groupsTABLE 2. Vascular graft characteristics
rFVIIa dose
Vein graft
diameter (cm)*
Carotid artery
diameter (cm)*
Placebo 0.38  0.05 0.14  0.02
20 mg/kg 0.40  0.05 0.14  0.02
90 mg/kg 0.39  0.06 0.14  0.02
300 mg/kg 0.38  0.07 0.14  0.02
rFVIIa,Recombinant factor VIIa. *n¼ 16 per group except for placebo (n¼ 15) and 90 mg/k
kg ¼ 7, and 300 mg/kg ¼ 1. zP<.05 compared with placebo at the same time point.
420 The Journal of Thoracic and Cardiovascular Surg(Table 1). ACTwas appropriately elevated in all groups after
heparin administration. All groups experienced slight
decreases in arterial pressures and decreased hemoglobin
concentrations as a result of anesthesia and surgery. There
were no differences between groups with the exception of
a slightly reduced mean arterial pressure in the rFVIIa
90 mg/kg group (Table 1).
Graft patency and flow. Theaveragediameter of the carotid
arteries (0.14 0.02 cm) and vein grafts (0.39 0.06 cm)was
similar between groups (Table 2). Graft patency (defined as
number of grafts patent/total number of grafts*100) was high-
est in the placebo group and lowest in the rFVIIa 300 mg/kg
group (Figure 1; 93.8% vs 6.3%; P<.05). Patency in the 20
and 90 mg/kg dose groups was intermediate (81.3% vs
43.8%; P<.05). At the time of visual inspection, the grafts
were patent or occluded with thrombus, and in all cases the
thromboses were confined to the anastomotic site; there was
no evidence of thromboses in other vessels. When calculated
as flow/total number grafts, flow was significantly reduced in
the high-dose rFVIIa group, but when calculated as flow/
open graft, there were no significant differences between
groups (Table 2).
Factor VII activity levels. There were no differences in
factor VII activity levels between groups before drug (or
placebo) administration (Figure 2). Factor VII activity levels
increased significantly in a dose-dependent fashion in all
groups after rFVIIa administration, with the highest levels
in the 300 mg/kg group (Figure 2).Protocol 2: Bilateral Graft Protocol
In the animals undergoing bilateral anastomoses (n ¼ 8
animals per group), there were no significant differences
between the placebo and the rFVIIa 300 mg/kg groups in
physiologic variables before or after heparin administra-
tion, with the exception of ACT (Table 1). In the rFVIIa-
treated animals, the incidence of occlusion of vein grafts
and arterial anastomoses was significantly higher than in
the placebo group (vein 87.5% rFVIIa vs 12.5% placebo;
artery 87.5% rFVIIa vs 25% placebo; P< .05 for both).
The average vein graft diameter (0.40  0.13 cm), carotid
artery diameter (0.15  0.02 cm), and graft flow per
patent graft (34.9  8.0 mL/min) were similar to those in
protocol 1.Average graft
flow (mL/min)*
Graft flow per patent
graft (mL/min)y
32.5  13.8 34.7  11.2
29.4  16.8 36.1  9.4
20.6  20.8 35.4  13.7
1.8  7.2z 28.5
g (n¼ 12). yNumber of patent grafts per group is placebo¼ 15, 20 mg/kg¼ 13, 90 mg/
ery c August 2011
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FIGURE 1. Vein graft patency (defined as number of grafts patent/total
number of grafts*100) was significantly reduced in a dose-dependent fash-
ion after rFVIIa. *P<.05 compared with placebo. yP<.05 compared with
20 m/kg. zP<.05 compared with 90 m/kg. CI, 95% Confidence interval.
Mazer et al Evolving Technology/Basic ScienceDISCUSSION
This study demonstrates that administration of rFVIIa
was associated with increased thrombosis and decreased
graft patency in a rabbit model of fresh vascular anastomo-
ses. A clear dose response was observed, with an inverse
relationship between vascular graft patency and rFVIIa
dose and serum drug levels. The lowest dose of rFVIIa
(20 mg/kg) did not result in a significant increase in graft
occlusion relative to placebo controls in this model. At
the highest dose (300 mg/kg), both venous grafts and simple
end-to-end arterial anastomoses experienced a similar
degree of occlusion, suggesting that the thrombotic effect
was independent of the type of anastomosis. The range of
rFVIIa doses used in this study encompasses the range of
doses administered clinically for patients with hemophilia
(90 mg/kg),6 patients undergoing cardiac surgery (11–180
mg/kg),3 and patients with trauma.11 Our results suggest
that higher doses of rFVIIa may detrimentally influencePlasma Factor VII Levels
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FIGURE 2. Plasma factor VII activity levels increased significantly after
1 of 3 doses of rFVIIa. *P<.05 compared with placebo at the same time
point. yP<.05 compared with 20 mg/kg and 90 mg/kg at the same time
point. zP<.05 compared with baseline value.
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secure hemostasis in patients with new vascular anastomo-
ses, the lowest effective dose should be given. Furthermore,
clinical safety evaluations of rFVIIa in patients with cardio-
vascular disease should include a range of doses and assess-
ment of graft patency.
Use of recombinant FVIIa has been reported in a variety of
cardiovascular surgical settings, predominantly as case reports
or case-cohort studies. In most of these studies, a reduction in
postoperative bleeding was reported in patients with intracta-
ble blood losswho received rFVIIa.However, the total number
of cases of rFVIIa use in cardiac surgery is still relatively
small. For example, the first randomized placebo-controlled
trial that assessed rFVIIa in cardiac surgery treated only 10
patients with rFVIIa (90 mg/kg).1 In this study, the transfusion
requirements were significantly reduced with rFVIIa, but vas-
cular graft patency was not assessed. The CRAFT study of
more than 500 patients undergoing cardiac surgery in Canada
showed a reduction in median allogeneic red blood cell unit
transfusions from 8 to 2 units after rVIIa treatment.4 Although
the morbidity and mortality rates were greater than 30%, this
was thought to be within the range expected from a separate
cohort of comparable non-rVIIa–treated patients. Predictors
of complications were preoperative hemodynamic instability
and red blood cell transfusion, and predictors of nonresponse
to rVIIawere pretreatment coagulopathy andmassive transfu-
sion. A recently reported randomized clinical trial of rVIIa in
172 patients bleeding after cardiac surgery found a signifi-
cantly reduced requirement for reoperation or allogeneic
blood products, and a higher incidence of critical serious
adverse events, including stroke, with rVIIa treatment.5 Doses
as low as 11 to 21 mg/kg have also been used to treat bleeding
in cardiac surgical patients.3Recent guideline documents have
suggested a weak recommendation, based on low-quality
evidence, for the use of rFVIIa as rescue therapy for select
patients with refractory hemorrhage unresponsive to standard
hemostatic therapies.12-14
The mechanism by which rFVIIa promotes hemostasis at
the site of fresh vascular anastomoses and injury is likely
due to enhanced local thrombin generation from activated
platelets and to direct activation of Factor X after complexing
with tissue factor at the site of injury.15 Such a mechanism
may have also contributed to rFVIIa-mediated thrombosis
in a rabbit model of vascular injury to the common carotid
artery.16 In addition to concerns about formation of thrombus
at fresh vascular anastomotic sites, there is also laboratory and
clinical evidence to suggest that rFVIIamay also promote oc-
clusion of nonatherosclerotic vessels. In clinical trials that as-
sessed rFVIIa, a significantly higher incidence of remote
arterial thromboses was observed in patients who received
rFVIIa for intracerebral hemorrhage17 or cardiac surgery.18,19
In a recent review of randomized clinical trials, arterial
thromboembolic events were reported to occur more
frequently with rFVIIa use.19 The majority were coronaryrdiovascular Surgery c Volume 142, Number 2 421
Evolving Technology/Basic Science Mazer et al
E
T
/B
Sischemic events, occurring 2.4 times more frequently in
rFVIIa-treated patients.19 Elevated factor VIIa levels have
been associatedwith retinal vein occlusion.20 In another anal-
ysis of thromboembolic events with rFVIIa administration
that were reported to the Food andDrugAdministration, arte-
rial thromboses (eg,myocardial infarctionand stroke) also ac-
counted for the largest number.21 Death was thought to be
related to thromboembolic events in over half of the cases,
supporting the clinical severity of these events.21 Although
the total numberof reported thrombotic adverse events related
to rFVIIamight be felt to be low, it is possible thatmanymore
have gone unreported. Our results suggest that safety evalua-
tions of future clinical studies of rFVIIa in patients with car-
diovascular disease should include specific assessment of
graft patency. Myocardial infarction may not be an adequate
surrogate measure of graft patency because not all throm-
bosed grafts result in acute myocardial infarction. The need
for adequate clinical studies to assess drug safety is
emphasized by the current controversy regarding the safety
of aprotinin.7,8 As in other examples, the sample size
required to demonstrate efficacy is often smaller than that
required to demonstrate safety.
The model used for these experiments was adapted from
an establishedmodel of vein graft maturation andwas chosen
because of the similarity in vessel size to human coronaries.
There are many factors that can contribute to thrombosis for-
mation and early graft failure. The harvesting process can
cause tissue factor expression, fibrin deposition, platelet
and neutrophil adherence, and decreased tissue plasminogen
production.22 Vein grafts have been shown to have decreased
thrombomodulin activity, nitric oxide, and prostacyclin,
which enhance local thrombin generation and platelet activa-
tion, thus predisposing to early graft failure.23 Addition of
rFVIIa to this potentially thrombogenic environment could
add to the likelihood of subsequent graft failure.
This study has some important potential limitations, in-
cluding the number of animals used, relevance to human
vascular physiology, lack of clinical data, and use of only 1
time point for investigation. Although this is the largest ani-
mal study of graft patencywith rFVIIa, because of the sample
size and dosing regimen used, we cannot make conclusions
about intermediate doses (between 20 and 90 mg/kg). We
intentionally limited our observation period to 24 hours
postoperatively because the manifestations of rFVIIa would
likely be seen soon after its administration, and we wanted
to avoid other confounding factors.Our experiments involved
a recombinant human protein infused into rabbits, but human
factor VII is similar to many other species in its primary
amino acid sequence, domain organization, 3-dimensional
structure, and reactionwith anti-factorVII antisera.24 Rabbits
have been used in the early development of activated factor
VII, and to demonstrate that it is hemostatically effective,25
that it does not cause systemic activation of the coagulation
system, and to evaluate the efficacy of rFVIIa in various422 The Journal of Thoracic and Cardiovascular Surgbleeding syndromes.26 In addition, we chose this model
because it has been used to study relevant atherosclerotic
processes, such as restenosis, and the arterial and graft sizes
approximate those in human coronary arteries. However, un-
like some patients, these animals did not have microvascular
bleeding related to exposure to cardiopulmonary bypass or
oral antihemostatic agents, such as aspirin or clopidogrel.
Nonetheless, a high proportion of patients with postoperative
hemorrhage may have surgical bleeding and are not overtly
coagulopathic.27CONCLUSIONS
This study suggests that high doses of rFVIIa (300 and 90
mg/kg) are associated with an increased incidence of occlu-
sion of new vascular grafts. A clear dose-response effect
was observed, suggesting that higher dosesmay be associated
with increased thrombotic outcomes and that lower doses
(20 mg/kg) may be safer for use in cardiovascular surgery.
These findings require further validation in human subjects
and may help guide the design of future studies and clinical
use of rFVIIa.
The authors acknowledge the technical assistance of J. Colin
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